Advertisement Ventana collaborates with Pfizer, CST for lung cancer diagnosis - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ventana collaborates with Pfizer, CST for lung cancer diagnosis

Ventana Medical Systems, a unit of the Roche Group, has signed a deal with Pfizer and license agreement with Cell Signaling Technology (CST) to develop automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements.

The test is intended to identify non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer’s XalkorI (crizotinib).

The assay will also measure the associated protein product, when an ALK gene rearrangement is present.

The Ventana ALK IHC diagnostic test will be based on CST’s D5F3 antibody and Ventana Optiview DAB detection, for performance on Ventana automated platforms.

Ventana Medical Systems president Mara G Aspinall said the collaboration would largely benefit patients suffering from NSCLC through biomarker identification.

"Our early development data suggests that the combination of CST’s D5F3 antibody and Ventana OptiView detection generates a highly sensitive assay that detects cases with very low expression of the ALK protein in lung tissue which means that Xalkori may be an appropriate treatment for those patients," Aspinall added.